BioCardia Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de BioCardia de 26.6% y 68.6% respectivamente, mientras que el BPA crecerá en un 34.6% al año.

Información clave

26.6%

Tasa de crecimiento de los beneficios

34.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.0%
Tasa de crecimiento de los ingresos	68.6%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	11 Nov 2023

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Oct 12

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Aug 24

Shareholders May Not Be So Generous With BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation And Here's Why

Jun 08

Is BioCardia (NASDAQ:BCDA) In A Good Position To Deliver On Growth Plans?

May 20

BioCardia issued U.S. patent for Helix Biotherapeutic Delivery system

Dec 30

BioCardia slips 11% on launch of direct offering

Dec 16

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:BCDA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	6	-19	N/A	N/A	1
12/31/2025	1	-19	N/A	N/A	1
12/31/2024	1	-16	N/A	N/A	1
12/31/2023	0	-12	-10	-10	N/A
9/30/2023	1	-13	-11	-11	N/A
6/30/2023	0	-13	-11	-11	N/A
3/31/2023	1	-12	-10	-10	N/A
12/31/2022	1	-12	-11	-11	N/A
9/30/2022	1	-12	-11	-11	N/A
6/30/2022	2	-12	-11	-11	N/A
3/31/2022	1	-13	-12	-11	N/A
12/31/2021	1	-13	-10	-10	N/A
9/30/2021	1	-12	-11	-11	N/A
6/30/2021	0	-13	-12	-12	N/A
3/31/2021	0	-13	-11	-11	N/A
12/31/2020	0	-15	-12	-12	N/A
9/30/2020	0	-16	-12	-12	N/A
6/30/2020	0	-15	-10	-10	N/A
3/31/2020	1	-16	-10	-10	N/A
12/31/2019	1	-15	-10	-9	N/A
9/30/2019	1	-15	-10	-9	N/A
6/30/2019	0	-15	-10	-10	N/A
3/31/2019	1	-14	-11	-10	N/A
12/31/2018	1	-14	-11	-11	N/A
9/30/2018	1	-14	-10	-10	N/A
6/30/2018	1	-13	-10	-10	N/A
3/31/2018	1	-13	-10	-9	N/A
12/31/2017	0	-12	-9	-9	N/A
9/30/2017	1	-12	N/A	-9	N/A
6/30/2017	1	-13	N/A	-8	N/A
3/31/2017	1	-12	N/A	-7	N/A
12/31/2016	1	-10	N/A	-6	N/A
9/30/2016	1	-7	N/A	-4	N/A
6/30/2016	1	-7	N/A	-5	N/A
3/31/2016	1	-6	N/A	-6	N/A
12/31/2015	1	-7	N/A	-7	N/A
3/31/2015	1	-10	N/A	-6	N/A
12/31/2014	1	-10	N/A	-6	N/A
12/31/2013	2	-6	N/A	-5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que BCDA siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que BCDA siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que BCDA siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (68.6% al año) de BCDA crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (68.6% al año) de BCDA crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de BCDA se prevé que sea elevada dentro de 3 años.

BioCardia Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates decrease by 74%, EPS upgraded

Consensus revenue estimates increase by 86%

Price target decreased by 24% to US$7.50

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$9.88

Recent updates

BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

BioCardia, Inc., Annual General Meeting, May 20, 2024

New major risk - Financial position

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioCardia, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

BioCardia Receives Determination Letter from the Staff that the Company Fails to Regain Compliance with the MVLS Requirement

BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

New major risk - Market cap size

BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $2.75 million.

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure

BioCardia, Inc. has filed a Follow-on Equity Offering in the amount of $1.3 million.

BioCardia, Inc. Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure

New major risk - Negative shareholders equity

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

BioCardia, Inc. Elects Bill Facteau as Class I Director

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Biocardia, Inc. Announces Completion of Enrollment in Phase Iii Cardiamp Hf Trial and Plans for Cardiamp Hf Trial Ii

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia Receives a Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

BioCardia, Inc. Announces Clarification and Next Steps on Its Autologous CardiAMP Cell Therapy Programs

Biocardia, Inc. Announces Interim Efficacy Results in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial

BioCardia, Inc., Annual General Meeting, Oct 18, 2023

Consensus revenue estimates decrease by 74%, EPS upgraded

New major risk - Revenue size

Second quarter 2023 earnings: EPS in line with expectations, revenues disappoint

BioCardia, Inc. to Report First Half, 2023 Results on Aug 09, 2023

New major risk - Share price stability

Biocardia, Inc. Announces Dsmb Recommendation to Pause New Enrollment in Phase III Pivotal Cardiamp Cell Therapy Heart Failure Trial While Additional Blinded Data Is Collected

BioCardia, Inc. Completes Submission of Cardiamp Cell Therapy System in Heart Failure to Japan's Pharmaceutical Medical Device Agency

New minor risk - Share price stability

Insider recently bought US$177k worth of stock

Consensus revenue estimates increase by 86%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

BioCardia, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 24% to US$7.50

BioCardia, Inc. announced that it expects to receive $3.564989 million in funding

BioCardia, Inc. Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure

Consensus forecasts updated

Consensus forecasts updated

Price target decreased to US$9.88

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioCardia, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Insufficient new directors

Biocardia®, Inc. to Present New Data from Cardiamp Cell Therapy for Heart Failure Pivotal Trial At the Heart Failure Society of America Annual Meeting

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?

Consensus revenue estimates increase by 138%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

BioCardia, Inc. to Report First Half, 2022 Results on Aug 10, 2022

BioCardia, Inc. Announces US Patent on Imaging System for Targeting Cardiac Therapies

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 64%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation

BioCardia, Inc. to Report Q1, 2022 Results on May 11, 2022

Price target decreased to US$10.63

Consensus forecasts updated

BioCardia, Inc. Announces FDA Approval of its IND for NK1R+ Mesenchymal Stem Cells

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocardia Receives No Objection Letter from Health Canada, Enabling Company to Expand Cardiamp Cell Therapy Heart Failure Trial into Canada

BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed